• biospring

Our investment in Kiniciti

We're pleased to announce our investment in Kiniciti, a Cell and Gene Therapy ("CGT") aggregator. We've had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market.


Biospring’s investment strategy is to identify long-term themes that are durable for ten to fifteen years. Cell and Gene Therapy services is a major theme within our pharma services vertical. The CGT market is expected to grow to $34B in size in 2030. Advances in sequencing and genomics have led to the ability to target specific genes in the treatment of a disease. Continued market growth is fueled by increased regulatory support, increased prevalence of chronic diseases, and increased R&D funding, among other factors.


We believe that Kiniciti's team is poised to successfully execute on this market opportunity. Kiniciti, led by Geoffrey Glass (Chief Executive Officer) and Jason Connor (Chief Strategy Officer), will industrialize their growing platform of services to serve the needs of global biopharmaceutical companies that are discovering and developing treatments.


We are excited to continue to work closely with Kiniciti's team as we add capabilities to the platform. Join us for a discussion with Geoff Glass on 11/17 at 11 am EST. We will discuss Kiniciti's vision for the future of Cell and Gene Therapy and some exciting company updates.

Kiniciti's Co-Founders: Geoffrey Glass (CEO) & Jason Connor (CSO)



Learn more:

  • The official press release can be found here.

  • Register for our fireside chat with Geoff Glass here.

  • Read our primer on CGT here.

About Kiniciti


Kiniciti, a platform company of leading private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners, invests in and partners with companies that have the potential to transform and strengthen the cell and gene therapy ecosystem. With a highly tailored, collaborative and flexible investment and strategic support model, Kiniciti aims to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The company’s leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector. For more information, visit kiniciti.com.